MORRIS PLAINS, N.J., June 2, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that 4 presentations will be given at the 16th Congress of the European Hematology Association, scheduled for June 9 – 12, 2011, in London, United Kingdom.
